Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

20101,795 citationsJournal Article

Authors

Jean‐Yves Douillard · Marqués de Valdecilla University Hospital

Salvatore Siena · Marqués de Valdecilla University Hospital

James T. Cassidy · Marqués de Valdecilla University Hospital

Josep Tabernero · Marqués de Valdecilla University Hospital

Ronald L. Burkes · Marqués de Valdecilla University Hospital

Mario Barugel · Marqués de Valdecilla University Hospital

Yves Humblet

Abstract

This study demonstrated that panitumumab-FOLFOX4 was well tolerated and significantly improved PFS in patients with WT KRAS tumors and underscores the importance of KRAS testing for patients with mCRC.

Topics & Keywords

Colorectal Cancer Treatments and Studies Cancer Treatment and Pharmacology Genetic factors in colorectal cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 28, Issue 31, pp. 4697-4705

DOI: 10.1200/jco.2009.27.4860

Field-Weighted Citation Impact: 73.75